MRI of hepatocellular carcinoma: An update of current practices

Diagnostic and Interventional Radiology

Volumn 20, Issue 3, 2014, Pages 209-221

  Arif Tiwari, Hina ^a   Kalb, Bobby ^a   Chundru, Surya ^a   Sharma, Puneet ^a   Costello, James ^a   Guessner, Rainner W ^a   Martin, Diego R ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOLINIUM CHELATE; GADOXETIC ACID; CONTRAST MEDIUM;

CANCER STAGING; CHEMOEMBOLIZATION; CHOLESTASIS; CHRONIC LIVER DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; ECHOGRAPHY; FOLLOW UP; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER NODULE; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN DONOR; RADIOFREQUENCY ABLATION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; BIOPSY; CARCINOMA, HEPATOCELLULAR; FEMALE; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; MALE; PATHOLOGY; PULSED RADIOFREQUENCY TREATMENT; SCINTISCANNING; VASCULARIZATION;

BIOPSY; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; MALE; PULSED RADIOFREQUENCY TREATMENT;

EID: 84899763537     PISSN: 13053825     EISSN: 13053612     Source Type: Journal    
DOI: 10.5152/dir.2014.13370     Document Type: Review

References (52)

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27:1485-1491. [CrossRef]
2. Ayyappan AP, Jhaveri KS. CT and MRI of hepatocellular carcinoma: an update. Expert Rev Anticancer Ther 2010; 10:507-519. [CrossRef]
3. Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247:311-330. [CrossRef]
4. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-699. [CrossRef]
5. Digumarthy SR, Sahani DV, Saini S. MRI in detection of hepatocellular carcinoma (HCC). Cancer Imaging 2005; 5:20-24. [CrossRef]
6. Yu NC, Chaudhari V, Raman SS, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol 2011; 9:161-167. [CrossRef]
7. Ayuso C, Rimola J, Garcia-Criado A. Imaging of HCC. Abdom Imaging 2012; 37:215-230. [CrossRef]
8. Kim KA, Kim MJ, Choi JY, Chung YE. Development of hepatocellular carcinomas in patients with absence of tumors on a prior ultrasound examination. Eur J Radiol 2012; 81:1450-1454. [CrossRef]
9. Lee KH, O'Malley ME, Haider MA, Hanbidge A. Triple-phase MDCT of hepatocellular carcinoma. AJR Am J Roentgenol 2004; 182:643-649. [CrossRef]
10. Solomon R. Contrast-induced acute kidney injury: is there a risk after intravenous contrast? Clin J Am Soc Nephrol 2008; 3:1242-1243. [CrossRef]
11. Pitton MB, Kloeckner R, Herber S, Otto G, Kreitner KF, Dueber C. MRI versus 64-row MDCT for diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009; 15:6044-6051. [CrossRef]
12. Purysko AS, Remer EM, Coppa CP, Leão Filho HM, Thupili CR, Veniero JC. LIRADS: a case-based review of the new categorization of liver findings in patients with end-stage liver disease. Radiographics 2012; 32:1977-1995. [CrossRef]
13. Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38:1034-1042. [CrossRef]
14. Khalili K, Kim TK, Jang HJ, et al. Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011; 54:723-728. [CrossRef]
15. Becker-Weidman DJ, Kalb B, Sharma P, et al. Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging--comparison to prior same-center results after MR systems improvements. Radiology 2011; 261:824-833. [CrossRef]
16. Martin DR, Krishnamoorthy S, Kalb B, et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 2010; 31:440-446. [CrossRef]
17. Catalano OA, Choy G, Zhu A, Hahn PF, Sahani DV. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology 2010; 254:154-162. [CrossRef]
18. Earls JP, Rofsky NM, DeCorato DR, Krinsky GA, Weinreb JC. Hepatic arterial-phase dynamic gadolinium-enhanced MR imaging: optimization with a test examination and a power injector. Radiology 1997; 202:268-273.
19. Sharma P, Kitajima HD, Kalb B, Martin DR. Gadolinium-enhanced imaging of liver tumors and manifestations of hepatitis: pharmacodynamic and technical considerations. Top Magn Reson Imaging 2009; 20:71-78. [CrossRef]
20. OPTN policy management. Available at: http://optn.transplant.hrsa.gov/policiesAndBylaws/ poli cies.asp. Accessed March 1, 2012.
21. Lauenstein TC, Sharma P, Hughes T, Heberlein K, Tudorascu D, Martin DR. Evaluation of optimized inversion-recovery fat-suppression techniques for T2-weighted abdominal MR imaging. J Magn Reson Imaging 2008; 27:1448-1454. [CrossRef]
22. Udayasankar UK, Martin D, Lauenstein T, et al. Role of spectral presaturation attenuated inversion-recovery fat-suppressed T2-weighted MR imaging in active inflammatory bowel disease. J Magn Reson Imaging 2008; 28:1133-1140. [CrossRef]
23. Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 2009; 29:1725-1748. [CrossRef]
24. Le Moigne F, Durieux M, Bancel B, et al. Impact of diffusion-weighted MR imaging on the characterization of small hepatocellular carcinoma in the cirrhotic liver. Magn Reson Imaging 2012; 30:656-665. [CrossRef]
25. Qu JR, Li HL, Shao NN, et al. Additional diffusion-weighted imaging in the detection of new, very small hepatocellular carcinoma lesions after interventional therapy compared with conventional 3 T MRI alone. Clin Radiol 2012; 67:669-674. [CrossRef]
26. Saranathan M, Rettmann DW, Hargreaves BA, Clarke SE, Vasanawala SS. Differential Subsampling with Cartesian Ordering (DISCO): a high spatio-temporal resolution Dixon imaging sequence for multiphasic contrast enhanced abdominal imaging. J Magn Reson Imaging 2012; 35:1484-1492. [CrossRef]
27. Mori K, Yoshioka H, Takahashi N, et al. Triple arterial phase dynamic MRI with sensitivity encoding for hypervascular hepatocellular carcinoma: comparison of the diagnostic accuracy among the early, middle, late, and whole triple arterial phase imaging. AJR Am J Roentgenol 2005; 184:63-69. [CrossRef]
28. Chandarana H, Block T, Rosenkrantz A, et al. Free-breathing radial 3D fat-suppressed T1-weighted gradient echo sequence: a viable alternative for contrast-enhanced liver imaging in patients unable to suspend respiration. Invest Radiol 2011; 46:648-653. [CrossRef]
29. Berman BP, Li Z, Altbach MI, et al. How to stack stars: a variable center-dense k-space trajectory for 3D MRI. Paper presented at: 2013 Annual Meeting of International Society for Magnetic Resonance in Medicine; April 23, 2013; Salt Lake City, USA.
30. Lauenstein TC, Salman K, Morreira R, et al. Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. AJR Am J Roentgenol 2007; 189:663-670. [CrossRef]
31. Kelekis NL, Semelka RC, Worawattanakul S, et al. Hepatocellular carcinoma in North America: a multiinstitutional study of appearance on T1-weighted, T2-weighted, and serial gadolinium-enhanced gradient-echo images. AJR Am J Roentgenol 1998; 170:1005-1013. [CrossRef]
32. Hussain HK, Londy FJ, Francis IR, et al. Hepatic arterial phase MR imaging with automated bolus-detection three-dimensional fast gradient-recalled-echo sequence: comparison with test-bolus method. Radiology 2003; 226:558-566. [CrossRef]
33. Van den Bos IC, Hussain SM, Dwarkasing RS, et al. MR imaging of hepatocellular carcinoma: relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement patterns. J Magn Reson Imaging 2007; 26:1548-1555. [CrossRef]
34. Kalb B, Becker-Weidman DJ, Chundru S, et al. Magnetic resonance imaging of HCC: predictive findings of post-transplant tumor recurrence in a screening population. Paper presented at: 2012 Annual Meeting of International Society for Magnetic Resonance in Medicine; May 8, 2012; Melbourne, Australia.
35. Nakanishi M, Chuma M, Hige S, et al. Relationship between diffusion-weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma. Ann Surg Oncol 2012; 19:1302-1309. [CrossRef]
36. Kanematsu M, Semelka RC, Leonardou P, Mastropasqua M, Lee JK. Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging 2003; 18:189-195. [CrossRef]
37. Myung SJ, Yoon JH, Kim KM, et al. Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments. Hepatogastroenterology 2006; 53:266-270.
38. American College of Radiology. Quality and safety resources: Liver Imaging-Reporting and Data System. Available at: http://www.acr.org/Quality-Safety/Resources/ LIRADS. Accessed March 1, 2011.
39. Cruite I, Tang A, Sirlin CB. Imaging-based diagnostic systems for hepatocellular carcinoma. AJR Am J Roentgenol 2013; 201:41-55. [CrossRef]
40. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007; 7:2587-2596. [CrossRef]
41. Stigliano R, Burroughs AK. Should we biopsy each liver mass suspicious for HCC before liver transplantation?--no, please don't. J Hepatol 2005; 43:563-568. [CrossRef]
42. Chang S, Kim SH, Lim HK, et al. Needle tract implantation after percutaneous interventional procedures in hepatocellular carcinomas: lessons learned from a 10-year experience. Korean J Radiol 2008; 9:268-274. [CrossRef]
43. Chundru S, Kalb B, Arif-Tiwari H, Sharma P, Costello J, Martin DR. MRI of diffuse liver disease: the common and uncommon etiologies. Diagn Interv Radiol 2013; 19:479-487.
44. Van Ha TG. Transarterial chemoembolization for hepatocellular carcinoma. Semin Intervent Radiol 2009; 26:270-275. [CrossRef]
45. Kalva SP, Thabet A, Wicky S. Recent advances in transarterial therapy of primary and secondary liver malignancies. Radiographics 2008; 28:101-117. [CrossRef]
46. Kalb B, Chamsuddin A, Nazzal L, Sharma P, Martin DR. Chemoembolization follow-up of hepatocellular carcinoma with MR imaging: usefulness of evaluating enhancement features on one-month posttherapy MR imaging for predicting residual disease. J Vasc Interv Radiol 2010; 21:1396-1404. [CrossRef]
47. Khankan AA, Murakami T, Onishi H, et al. Hepatocellular carcinoma treated with radio frequency ablation: an early evaluation with magnetic resonance imaging. J Magn Reson Imaging 2008; 27:546-551. [CrossRef]
48. Lau WY, Yu SC, Lai EC, Leung TW. Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg 2006; 202:155-168. [CrossRef]
49. Kim SK, Lim HK, Kim YH, et al. Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging findings. Radiographics 2003; 23:107-121. [CrossRef]
50. Lau WY, Leung TWT, Yu SCH, Ho SKW. Percutaneous local ablative therapy for hepatocellular carcinoma. Ann Surg 2003; 273:171-179. [CrossRef]
51. Tatli S, Tapan U, Morrison PR, Silverman SG. Radiofrequency ablation: technique and clinical applications. Diagn Interv Radiol 2012; 18:508-516.
52. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52-60. [CrossRef]